<DOC>
	<DOCNO>NCT02655614</DOCNO>
	<brief_summary>This first-in-human , double-blind , placebo-controlled Phase I study conducted participant amyotrophic lateral sclerosis ( ALS ) explore safety , tolerability , pharmacokinetic ( PK ) property GDC-0134 . It include two component : Single-Ascending-Dose ( SAD ) stage Multiple-Ascending-Dose ( MAD ) stage .</brief_summary>
	<brief_title>A Study GDC-0134 Determine Initial Safety , Tolerability , Pharmacokinetic Parameters Participants With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Male female participant diagnosis possible , laboratorysupported probable , probable , definite ALS accord modify El Escorial criterion Upright force vital capacity least 60 percent ( % ) Ability fast food 8 hour prior dose 2 hour dose Currently take riluzole unless stable dose 3 month prior screen without current liver enzyme liver function abnormality Positive hepatitis C antibody , hepatitis B surface antigen , human immunodeficiency virus ( HIV ) antibody Clinically significant thrombocytopenia Currently take nutritional/herbal supplement , except overthecounter vitamin within Recommended Dietary Allowance ( RDA ) , unless discontinue least 7 day prior Day âˆ’ 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>